TEVIMBRA approuvé aux États-Unis pour le traitement de première intention du carcinome épidermoïde de l'œsophage avancé en association avec la chimiothérapie
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2025
0mins
Source: Businesswire
FDA Approval of TEVIMBRA: BeiGene, Ltd. has received FDA approval for TEVIMBRA® (tislelizumab-jsgr) in combination with chemotherapy as a first-line treatment for adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) expressing PD-L1 (≥ 1), based on significant survival improvements shown in the RATIONALE-306 study.
Safety and Adverse Effects: The approval highlights the importance of monitoring for serious immune-mediated adverse reactions associated with TEVIMBRA, including pneumonia, colitis, and thyroid disorders, which may require treatment interruptions or discontinuations depending on severity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
